ProMIS Neurosciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

WARRANTS

WARRANTS

3 Months Ended

Mar. 31, 2026

7.	WARRANTS

As of March 31, 2026, outstanding Common Share warrants and exercise prices related to unit offerings are as follows:


Exercise		Number of
Price $		Warrants	Expiry date
US$315.00		20,948	August 2026
US$240.00		5,868	August 2026
US$50.50		314,170	January 2027
US$187.50		13,831	April 2028
US$152.50		2,767	April 2028
US$43.75		449,084	February 2029
US$62.50		314,170	July 2029
US$31.25		1,129,324	July 2030
US$14.40		6,915,296	February 2031
US$0.25		74,673	None
US$0.0001		100,000	None
		9,340,131

There were no warrant exercises in the three months ended March 31, 2026 or 2025. Refer to Note 6 for discussion on the issuance of 6,915,296 Common Share Warrants and 100,000 Pre-Funded Warrants in the January 2026 PIPE. During the three months ended March 31, 2026, 314,170 warrants expired without being exercised.